Phase IIa, open-label, multi-center study of the DNA polymerase theta inhibitor ART6043 administered orally in combination with olaparib to patients with HER2-negative breast cancer with a germline BRCA1/2 mutation (randomized expansion of study NCT05898399).

ART6043 - Artios Pharma

Lynparza (olaparib) - Merck (MSD), AstraZeneca

https://www.asco.org/abstracts-presentations/266622

Mark Robson; Colette Baxter; Nicola Little; Paul Dickinson; Mary Stuart; Graeme Smith; Ian Smith; Timothy Yap; Gaorav Gupta; Raquel Andrés; Eva Carrasco Carrascal; Bryony Harrop; Desiree Headley; Helen Millward; Samantha Skelton

Apr 21, 2026